Literature DB >> 19402169

Radiotherapy in adrenocortical carcinoma.

Buelent Polat1, Martin Fassnacht, Leo Pfreundner, Matthias Guckenberger, Klaus Bratengeier, Sarah Johanssen, Werner Kenn, Stefanie Hahner, Bruno Allolio, Michael Flentje.   

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy, and patients with ACC have a poor prognosis. Even after radical surgery, up to 85% of patients develop recurrent disease. Systemic treatment options still have limited efficacy. Because the role of radiotherapy is not defined well and because ACC often is considered radioresistant, the authors reviewed the available data on radiotherapy for ACC. Original articles and reviews were identified using a PubMed search strategy that included the period up to July 2008. Ten articles were identified that covered radiotherapy in a total of 129 patients with ACC (64 patients received postoperative irradiation, and 65 patients received palliative therapy for advanced disease). In addition, 26 patients were identified in the German ACC Registry who received palliative radiotherapy. Furthermore, patterns of failure after adjuvant radiotherapy were investigated, and the authors provided recommendations for patient selection, treatment planning, and treatment protocols. In an adjuvant setting, postoperative radiotherapy was able to prevent local recurrence in the majority of patients. In those with advanced disease, a response to radiotherapy was observed in 57% of patients who received palliative radiotherapy. Therefore, the authors concluded that radiotherapy may play an important role in the care of patients with ACC. Until better evidence is available, the authors recommended the following approach: Adjuvant radiotherapy to the tumor bed should be considered in patients at high risk for local recurrence (eg, incomplete/R1 resection); a total dose of >40 grays (Gy) with single fractions of 1.8 Gy to 2 Gy should be administered (including a boost volume to reach from 50 Gy to 60 Gy in individual patients); and radiotherapy in a palliative setting may be used for symptomatic metastases to bone, brain, or vena cava obstruction. With state-of-the-art technology, acute and long-term toxicities mostly were mild to moderate. However, the authors concluded that prospective investigations would be required to fully define the therapeutic potential of this important treatment option.

Entities:  

Mesh:

Year:  2009        PMID: 19402169     DOI: 10.1002/cncr.24331

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma.

Authors:  Barbra S Miller; Kathleen M Ignatoski; Stephanie Daignault; Ceit Lindland; Megan Doherty; Paul G Gauger; Gary D Hammer; Stewart C Wang; Gerard M Doherty
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

Review 2.  Multi-organ resection for locally advanced adrenocortical cancer: surgical strategy and literature review.

Authors:  F Guida; M Clemente; L Valvano; C Napolitano
Journal:  G Chir       Date:  2015 Sep-Oct

3.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

4.  Mouse embryonic stem cells, but not somatic cells, predominantly use homologous recombination to repair double-strand DNA breaks.

Authors:  Elisia D Tichy; Resmi Pillai; Li Deng; Li Liang; Jay Tischfield; Sandy J Schwemberger; George F Babcock; Peter J Stambrook
Journal:  Stem Cells Dev       Date:  2010-08-05       Impact factor: 3.272

Review 5.  Adrenocortical carcinoma: the management of metastatic disease.

Authors:  André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri
Journal:  Crit Rev Oncol Hematol       Date:  2014-06-04       Impact factor: 6.312

Review 6.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

7.  Operative management for recurrent and metastatic adrenocortical carcinoma.

Authors:  Nicole M Datrice; Russell C Langan; R Taylor Ripley; Clinton D Kemp; Seth M Steinberg; Bradford J Wood; Steven K Libutti; Tito Fojo; David S Schrump; Itzhak Avital
Journal:  J Surg Oncol       Date:  2011-12-20       Impact factor: 3.454

8.  Response to radiation therapy in adrenocortical carcinoma.

Authors:  I G C Hermsen; Y E Groenen; M W Dercksen; J Theuws; H R Haak
Journal:  J Endocrinol Invest       Date:  2010-03-10       Impact factor: 4.256

9.  A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma.

Authors:  Mouhammed Amir Habra; Shamim Ejaz; Lei Feng; Prajnan Das; Ferhat Deniz; Elizabeth G Grubbs; Alexandria Phan; Steven G Waguespack; Montserrat Ayala-Ramirez; Camilo Jimenez; Nancy D Perrier; Jeffrey E Lee; Rena Vassilopoulou-Sellin
Journal:  J Clin Endocrinol Metab       Date:  2012-11-12       Impact factor: 5.958

10.  Unusual cause of paraparesis in a patient with Cushing's syndrome.

Authors:  Kush Dev Jarial; Chirag K Ahuja; Soham Mukherjee; Anil Bhansali
Journal:  BMJ Case Rep       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.